Results 71 to 80 of about 38,272 (314)

Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure

Cardiovascular Diabetology
Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear.
Dennis Wang, Anna V. Naumova, D. Isquith, Jamie Sapp, K. A. Huynh, Isabella Tucker, N. Balu, Anna Voronyuk, Baocheng Chu, Karen Ordovas, Charles Maynard, Rong Tian, Xue-qiao Zhao, Francis Kim   +13 more
semanticscholar   +2 more sources

An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy

Frontiers in Endocrinology, 2022
Dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new type of oral hypoglycemic drugs which can promote glucose excretion in the kidney.
Zhenyu Bai, Ting Xie, Tianhao Liu, Zedong Chen, Linde Yu, Linde Yu, Chao Zhang, Jincheng Luo, Liguo Chen, Xiaoshan Zhao, Ya Xiao   +10 more
doaj   +1 more source

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial

British medical journal
Objective To assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes. Design Multicentre, double blind, randomised, placebo controlled trial.
Yuejun Liu, Ying Chen, Jia-yun Ma, Jiayang Lin, Changqin Liu, Xuejun Li, Yong Xu, Hongyu Kuang, Li-xin Shi, Yao-ming Xue, Bo Feng, Dalong Zhu, Guang Wang, Jinkui Yang, Xinhua Xiao, Xu Yu, Jiaqiang Zhou, Yuqian Bao, Qing Su, Minzhi Lyu, Xiaomu Li, Huijie Zhang, Xiaoying Li   +22 more
semanticscholar   +1 more source

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

Circulation, 2019
BACKGROUND In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for
Eri Toda Kato, Michael G. Silverman, Ofri Mosenzon, Thomas A. Zelniker, A. Cahn, Remo H M Furtado, J. Kuder, S. Murphy, Deepak L. Bhatt, L. Leiter, D. McGuire, John P H Wilding, Marc P. Bonaca, C. Ruff, Akshay S. Desai, S. Goto, P. Johansson, I. Gause-Nilsson, P. Johanson, A. Langkilde, I. Raz, M. Sabatine, S. Wiviott   +22 more
semanticscholar   +1 more source

Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea

ERJ Open Research, 2023
Optimising medical cardiac treatment for central sleep apnoea (CSA) in patients with chronic heart failure (CHF) remains under debate with an expert-grade C recommendation [1, 2]. Investigating the impact of established and emerging heart failure therapy
D. Jaffuel, Yannick Bouchaut, J. Mallet, Célia Vidal, Nicolas Molinari, A. Bourdin, F. Roubille   +6 more
semanticscholar   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Dapagliflozin-induced abnormal uterine bleeding in a patient with dilated cardiomyopathy and chronic heart failure: a case report

Journal of International Medical Research
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are extensively used in the management of heart failure because of their cardiovascular benefits. Adverse drug reactions associated with dapagliflozin include diabetic ketoacidosis, fungal infections, and
Shikun Gong, Shunan Zhang, Yun Ye, Meiling Wu   +3 more
doaj   +1 more source

Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF):protocol for a randomised controlled double-blind cross-over trial [PDF]

, 2017
Introduction: Type 2 diabetes (T2D) and heart failure (HF) are a frequent combination, where treatment options remain limited. There has been increasing interest around the sodium-glucose co-transporter 2 (SGLT2) inhibitors and their use in patients with
Baig, Fatima, Choy, Anna-Maria, Lang, Chim C., McCrimmon, Rory J., Mordi, Ify R., Mordi, Natalie A., Singh, Jagdeep S., Struthers, Allan D.   +7 more
core   +2 more sources

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan

Kidney International Reports
Introduction: Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney disease (ADPKD) has not been established ...
Kiyotaka Uchiyama, Daisuke Kamano, Tomoki Nagasaka, Eriko Yoshida Hama, Ryoichi Shirai, Rena Sumura, Ei Kusahana, Akane Yanai, Takashin Nakayama, Takahide Kimura, Rina Takahashi, Takahiro Kasai, Takaya Tajima, Koji Hosoya, Tatsuhiko Azegami, Shintaro Yamaguchi, Jun Yoshino, Jun Ito, Matsuhiko Hayashi, Takeshi Kanda, Yoshitaka Ishibashi, Naoki Washida, Hiroshi Itoh, Kaori Hayashi   +23 more
doaj   +1 more source